Zealand Pharma shares slide as Jefferies cuts to Hold, slashes price target 37% By Investing.com
Jefferies downgraded Zealand Pharma A/S to Hold from Buy and cut its price target to DKK320 from DKK505, citing fewer near-term catalysts. The firm lowered survodutide Phase III success odds to 40% from 60% after disappointing data. Zealand shares fell 2.7% to DKK273.40 in Copenhagen.
How this was made
The 30-second read
Why it matters
The downgrade to Hold and the PT cut reflect lower modeled success odds and delayed catalyst timing (2027-2028), which can affect trading flows even without new company disclosures.
Market read
Traders can use the PT cut and revised probability-of-success to reassess near-term risk premium for Zealand’s obesity assets and timing of catalysts.
What to watch
Competitor obesity-drug data could shift relative positioning for petrelintide; if upcoming competitor results are less threatening than feared, the market’s read-across could reverse.
Background
The piece frames the move as an analyst-driven reset of near-term expectations for Zealand’s obesity pipeline after disappointing Phase III survodutide results.
Market effects
Reinforces risk-off sentiment toward obesity biotech programs when Phase III readouts disappoint and near-term catalysts are pushed out.
May weigh on Danish biotech sentiment versus the OMXC25 benchmark given the stated underperformance.
Could contribute to broader European small/mid-cap biotech valuation pressure if similar read-across occurs for obesity pipeline names.
Counterpoint
Jefferies still calls the long-term valuation attractive, citing net cash and rare disease assets, implying the downgrade may be more about timing than fundamental impairment.
Key entities
- companyZealand Pharma A/S
Danish biotech whose shares fell after Jefferies downgraded the stock and cut its price target based on obesity pipeline setbacks.
- analyst_firmJefferies
Brokerage that downgraded Zealand to Hold and reduced the probability of success for survodutide.
